® is a second-generation atypical antipsychotic. A seemingly random and uncontrollable "ghost peak" that vary from below the detection limit to ∼0.2% was observed occasionally during the development of HPLC method for brexpiprazole drug substance. The "ghost peak" was finally characterized as a syn head-to-tail dimer of brexpiprazole by UV, IR, LC-MS/TOF, 1D
Introduction
Brexpiprazole (OPC-34712, Fig. 1.) is a novel serotonin-dopamine activity modulator, which has been approved by FDA for the treatment of schizophrenia and as an adjunctive treatment for depression in 2015 [1, 2] . During the development of the related substance HPLC method for brexpiprazole drug substance, a "ghost peak" was intermittently observed at a relative retention time (RRT) of 1.60. HPLC results showed that the amount of this "ghost peak" could vary from below the detection limit to ∼0.2%
for the very same batch of the drug substance after initial investigation.
Controllability is fundamental to all aspects of production and analysis in the highly regulated pharmaceutical industry. High performance liquid chromatography (HPLC) enables the analysis of a mixture of analytes possessing a broad range of polarity and retention characteristics in a single run. However, HPLC methods can sometimes be plagued with seemingly random and unpredictable "ghost peaks" problems, particularly if the analyst does not appreciate the sensitive mechanisms involved [3] . The sources of these "ghost peaks" include sample degradation, instrumentation, solvents, glassware, and closure systems [4] . Recently, several groups reported that analytical solution degradation caused by non-obvious reasons was one of the contributing factors for inducing such "ghost peaks" [5] [6] [7] [8] . The behavior of the unknown peak presented at RRT 1.60 in brexpiprazole renders itself another case of ghost peak occurrence. The uncontrollable occurrence of this "ghost peak" had a profound negative impact upon the robustness of the analytical method. And as per the stringent regulatory requirements recommended by ICH, it is mandatory to identify and structurally characterize any unknown impurity formed during production which is ≥0.1% [9] . Therefore, the aim of this study was to elucidate the structure of the "ghost peak" and identify the root cause of its formation by LC-PDA, prepared HPLC, LC-MS/TOF and NMR. 
High performance liquid chromatography (analytical)
HPLC studies were carried out on LC-20AD liquid chromatograph (Shimadzu, Kyoto, Japan), which was equipped with a SPD-M20A prominence diode array detector and degasser (DGU-20A3). The output signal was monitored and processed using LCSolution software. The chromatographic separation was achieved on a SHIMADZU Shim-pack GIST C18 column (150 mm × 4.6mm, 5 μm) using a gradient program of ammonium acetate buffer (0.01M, the pH value of solution was adjusted to 4. dissociation experiments, keeping MS1 static, the precursor ion of interest was selected using the quadruple analyzer, and the product ions were analyzed using the TOF analyzer. Ultrahigh pure nitrogen gas was used as collision gas. LC method for LC-MS/MS studies was same with HPLC (section 2.2). However, to prevent condensation in the ionization source, the solvent flow into MS system was reduced from 1 ml/min to 500 μl/min by a diversion valve.
Nuclear magnetic resonance spectroscopy (NMR)
NMR spectra were recorded at 298 K on a Bruker AV 400 or Avance III 600 MHz spectrometer (Bruker BioSpin Corp., Billerica, MA, USA). All NMR spectra were 
FT-IR spectroscopy
The infrared spectroscopy data of brexpiprazole and the RRT 1.60 impurity were recorded in the solid state as KBr dispersion using Nicolet avatar 330 FT-IR spectrophotometer (Thermo Nicolet Corporation, Madison, USA) over the range of 4000-400 cm −1 .
Supplementary material
The supplementary material relating to this work contains FT-IR, 1D NMR ( 1 H, 13 C and DEPT) and 2D NMR ( 1 H-1 H COSY, HSQC, HMBC and ROESY) spectra of brexpiprazole and the RRT 1.60 impurity.
Results and discussion
3.1. Random occurrence of "ghost peak" from brexpiprazole solution
During the development stage of the related substance HPLC method for brexpiprazole, an unknown peak at RRT 1.60 was observed sporadically (Fig. 2) .
Although usually very small, the peak would sometimes appear at levels greater than 0.1% when compared to the brexpiprazole peak, creating a significant quality concern.
Due to its unpredictable nature of this unknown peak, it could be categorized as a "ghost peak" [4] . To unveil the mask of this "ghost peak", further investigations were initiated. On the other hand, we found out by chance that the analytes prepared at noon showed the highest levels of "ghost peak" and it can be avoided when this process was kept away from sunlight (Fig. 2) . All of these led to the hypothesis that sunlight could be the root cause of the "ghost peak".
LC-PDA/UV-MS/MS analysis
A brexpiprazole solution in 80% mobile phase B that displayed the RRT 1.60 "ghost peak" was analyzed by LC-PDA-Qtof MS and MS/MS. The UV spectrum of the "ghost peak" was very similar to that of brexpiprazole except that the band at 300-350 nm in brexpiprazole was nearly disappeared (Fig. 3) . It suggested that the RRT 1.60 species might be a degradation product of brexpiprazole and its formation was accompanied by some changes in the thianaphthene or quinolone chromophore. On the other hand, the full scan (+)-HR-ESI-MS spectrum of the RRT 1.60 species showed a Fig. 3 . Overlaid UV spectra of brexpiprazole and the RRT 1.60 "ghost peak" (extracted through LC-PDA spectrum). To facilitate further spectroscopic characterization and discuss possible formation mechanism of the RRT 1.60 species, a mechanism-based forced degradation outlined in Section 2.3 was performed. The brexpiprazole solution in 80% mobile phase B (5mg/ml, 100 ml) was exposed to direct sunlight for about 6 hours to regenerate the RRT 1.60 unknown impurity. The HPLC results showed that the amounts of the unknown impurity was formed up to 28%. The UV and MS/MS spectra of the stressgenerated degradant matched well with those of the RRT 1.60 impurity in the original sample solution, confirming that the "ghost peak" was indeed generated from brexpiprazole via the catalysis of sunlight. (C-O, stretching) and 751 cm −1 (=C-H, out-of-plane bending) (Fig. S2) . The absorption band at 1653 cm −1 corresponding to amide (O=C-NH) in brexpirazole (Fig. S3 ) was red shifted to 1684 cm −1 in this unknown impurity. Taken together with UV and HR-MS/MS spectra (Section 3.2), FT-IR data further revealed that the RRT 1.60 "ghost peak" was the dimerization product of brexpiprazole through quinolone fragment.
Due to their similarities in the frames and functional groups, complete NMR assignments of brexpiprazole were essential for the identification of this unknown impurity. The 1 H and 13 C NMR peak assignments and multiplicity for brexpirazole were tabulated in Table 1 (Fig. S4-10 ).
The 1 H-NMR spectrum of the unknown impurity ( Table 2 , Fig. S11 ) was similar to that of brexpirazole (Table 1) The HSQC data ( Table 2 , Fig. S15) showed that the signals at δH 3.62 (m, H2-4, 4') and 3.41 (m, H2-3, 3') were connected to the corresponding methine carbons at δC 43.97 and 42.19, respectively. The COSY experiment also indicated these two protons correlated to each other (Fig. S14) . The HMBC correlations ( Table 2 , Fig. S16 ) from It has been reported that substituted coumarin or 2-quinolone derivates can give rise to four isomeric dimers (syn head-to-head, anti head-to-head, anti head-to-tail, and syn head-to-tail) during photodimerization [13] [14] . The configuration of this "ghost peak" was determined as syn head-to-tail by the NOE correlations of H-1/H-6' (or H-1'/H-6) and H-5/H-8' (or H-5'/H-8) in the ROESY data (Fig. S17-18 ). 3.5. Proposed formation mechanism and prevention of the RRT 1.60 "ghost peak"
Based on the structure we characterized in section 3.4 ( Fig. 1) , the formation mechanism of RRT 1.60 "ghost peak" can be rationalized by photocatalytic [2+2] cycloadditions reaction. The [2+2] photocyclization begins with photoexcitation of the α, β-unsaturated ketone in one molecular of brexpiprazole to a singlet excited state (Fig.   6 ). The singlet state is very short lived, and then transit to the triplet state through intersystem crossing. At this point, the enone forms an exciplex with the ground-state alkene which from another molecular of brexpiprazole, eventually forming a triplet diradical intermediate. And the RRT 1.60 "ghost peak" was formed once spin inversion from the triplet diradical to the singlet diradical occurred [11, 12] . The hypothesis was further corroborated by the fact that the amount of the unknown impurity can reach up to 1.7% after the sample solution was exposed to direct sunlight for about five minutes at noon (Fig. S19) . According to the proposed formation mechanism of RRT 1.60 "ghost peak", it can be avoided by keep sample solution away from sunlight (Fig. S19 ).
Fig. 6.
Proposed formation mechanism of the RRT 1.60 "ghost peak"
Conclusion
Ghost peaks are often observed unexpectedly and intermittently in HPLC chromatograms, especially in the gradient mode. And these "ghost peaks" can pose a challenge to analytical scientists because they may arise from some non-obvious reasons. In this study, a "ghost peak" observed in HPLC chromatograms was isolated and characterized as a syn head-to-tail dimer of brexpiprazole by UV, IR, LC-MS/TOF, 1D and 2D NMR. Based on the structure we proposed, it was identified that the root cause for the undesirable occurrence of the RRT 1.60 "ghost peak" in brexpiprazole was due to photocatalytic [2+2] pericyclic reaction, which can be prevented by keeping analytes away from sunlight. We hope the results from this investigation may facilitate ghost peak investigations in other pharmaceutical analytical laboratories.
"Ghost peak" driven structural elucidation of a photocatalytic degradation product from brexpiprazole Tao 
